https://www.selleckchem.com/products/azd3965.html
005). Significant symptomatic improvements were observed in chest and abdominal discomfort with mosapride, in flatulence with rifaximin, and in chest discomfort with the combined groups. Adverse events were similar between the groups. Although rifaximin has an advantage in reducing gas, mosapride can help to decrease breath hydrogen concentration. Certain intestinal symptoms improved with mosapride alone or combined with rifaximin. Although rifaximin has an advantage in reducing gas, mosapride can help to decrease breath hydrogen concen
Like
Comment
Share
